반려동물 수술후 통증 관리 치료제 시장, 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global Companion Animal Postoperative Pain Management Therapeutics Market was valued at USD 133.5 million in 2023 and is projected to grow at a CAGR of 6.5% during the forecast period. The market's expansion is driven by the rising frequency of surgical procedures in companion animals. As pet ownership surges and veterinary care evolves, there's an escalating need for efficient post-surgery pain management solutions. For example, the American Pet Products Association (APPA) reports that pet ownership in the U.S. has soared to 85 million, with many pets undergoing surgeries each year. This increase in surgical procedures underscores the critical need for effective pain management, emphasizing the role of therapeutics in promoting animal welfare and recovery.

The overall companion animal postoperative pain management therapeutics industry is classified based on the drug class, route of administration, indication, animal type, distribution channel, and region.

The market for companion animal postoperative pain management therapeutics is segmented by drug class into NSAIDs, opioids, anesthetics, alpha-2 agonists, and other categories. In 2023, the NSAIDs segment led the market with a valuation of USD 103.7 million. Nonsteroidal anti-inflammatory drugs (NSAIDs) lead the market due to their proven efficacy and safety in alleviating pain and inflammation in pets. Their prominence is underscored by their substantial share in veterinary prescriptions, emphasizing their pivotal role in postoperative care. NSAIDs' established reputation in clinical applications, paired with continuous innovations in drug formulations, solidifies their leading market position.

The market is divided into oral, parenteral, and topical segments based on the route of administration. In 2023, the oral segment commanded the market with a dominant share of 57.1%. The oral segment's prominence stems from its convenience, straightforward administration, and effective pain alleviation. Veterinarians and pet owners favor oral therapeutics-be it tablets, capsules, or oral suspensions-for postoperative pain management due to their ease of administration over injectables or topicals. The segment's dominance is bolstered by heightened awareness of pain management in veterinary practices and innovations in oral drug formulations that enhance efficacy and safety.

In 2023, the U.S. led the North American market for companion animal postoperative pain management therapeutics, accounting for USD 59.2 million, with promising growth anticipated in the coming years. North America's leadership is attributed to its advanced veterinary infrastructure, high rates of pet ownership, and robust investments in R&D. The region's strong healthcare framework and the swift adoption of cutting-edge pain management solutions amplify its market share. An intensified focus on improving pets' quality of life, alongside rising awareness among pet owners about effective pain management, fuels the demand for advanced therapeutics.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising awareness of animal welfare
    • 3.2.1.2 Increasing pet ownership
    • 3.2.1.3 Development of novel therapeutics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Adverse effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 NSAIDs
• 5.3 Anesthetics
• 5.4 Opioids
• 5.5 Alpha-2 agonists
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral
• 6.4 Topical

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Dogs
• 7.3 Cats
• 7.4 Other animal types

Chapter 8 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Orthopedic surgery
• 8.3 Soft tissue surgery
• 8.4 Dental surgery
• 8.5 Oncologic surgery
• 8.6 Other surgeries

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Assisi Animal Health
• 11.2 Bayer AG
• 11.3 Bimeda Animal Health
• 11.4 Boehringer Ingelheim International GmbH
• 11.5 Ceva Sante Animale
• 11.6 Chanelle Pharma Group
• 11.7 Dechra Pharmaceuticals
• 11.8 Elanco Animal Health Incorporated
• 11.9 Merck Animal Health
• 11.10 Norbrook
• 11.11 SAVA Vet
• 11.12 Vetoquinol S.A.
• 11.13 Virbac Group
• 11.14 Zoetis Inc.